Survival after HeartMate 3 left ventricular assist device implantation: real‐world data from Europe

Survival of end-stage heart failure patients on left ventricular assist device (LVAD) support continuously increases. 1 Nowa-days, the HeartMate 3 (HM3, Abbott, Chicago, IL, USA) LVAD is most commonly implanted. Mehra et al . showed a 5 year survival of 58.4% in HM3 patients included in the extended-phase analysis of the MOMENTUM 3 trial. Patients included in this trial were treated in the United States. 2 LVAD patient selection and donor heart availability differ between United States and Europe. 3 In addition, outcomes in clinical trials may differ from those in common practice due to patient selection criteria and intensity of follow-up.